{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:36:55Z","timestamp":1792985815604,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-06839-0","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:25:39Z","timestamp":1773743139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rituximab-induced hypogammaglobulinemia in childhood nephrotic syndrome: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"185","author":[{"given":"Jason","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinnia","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cal","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelyne","family":"Ewusie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"South","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Bamhraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rauda","family":"AlKhoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Chanchlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"10","key":"6839_CR1","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.2215\/CJN.00380116","volume":"11","author":"THM Banh","year":"2016","unstructured":"Banh THM, Hussain-Shamsy N, Patel V et al (2016) Ethnic differences in incidence and outcomes of childhood nephrotic syndrome. Clin J Am Soc Nephrol 11(10):1760\u20131768. https:\/\/doi.org\/10.2215\/CJN.00380116","journal-title":"Clin J Am Soc Nephrol"},{"key":"6839_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2016.00039","author":"R Chanchlani","year":"2016","unstructured":"Chanchlani R, Parekh RS (2016) Ethnic differences in childhood nephrotic syndrome. Front Pediatr. https:\/\/doi.org\/10.3389\/fped.2016.00039","journal-title":"Front Pediatr"},{"issue":"10141","key":"6839_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392(10141):61\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(18)30536-1","journal-title":"Lancet"},{"issue":"9384","key":"6839_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362(9384):629\u2013639. https:\/\/doi.org\/10.1016\/S0140-6736(03)14184-0","journal-title":"Lancet"},{"issue":"4","key":"6839_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100(4):753\u2013779. https:\/\/doi.org\/10.1016\/j.kint.2021.05.015","journal-title":"Kidney Int"},{"issue":"3","key":"6839_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E et al (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38(3):877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05739-3","journal-title":"Pediatr Nephrol"},{"key":"6839_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM et al (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57:60\u201365. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.009","journal-title":"J Autoimmun"},{"issue":"2","key":"6839_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","volume":"13","author":"C Casulo","year":"2013","unstructured":"Casulo C, Maragulia J, Zelenetz AD (2013) Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 13(2):106\u2013111. https:\/\/doi.org\/10.1016\/j.clml.2012.11.011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"6839_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13519","volume":"23","author":"FK Chiou","year":"2019","unstructured":"Chiou FK, Beath SV, Patel M, Gupte GL (2019) Hypogammaglobulinemia and bacterial infections following pediatric post\u2010transplant lymphoproliferative disorder in the rituximab era. Pediatr Transplant 23(6):e13519. https:\/\/doi.org\/10.1111\/petr.13519","journal-title":"Pediatr Transplant"},{"issue":"1","key":"6839_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-019-0365-y","volume":"17","author":"AM Khojah","year":"2019","unstructured":"Khojah AM, Miller ML, Klein-Gitelman MS et al (2019) Rituximab-associated hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatr Rheumatol 17(1):61. https:\/\/doi.org\/10.1186\/s12969-019-0365-y","journal-title":"Pediatr Rheumatol"},{"issue":"23","key":"6839_CR11","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","volume":"382","author":"V Minard-Colin","year":"2020","unstructured":"Minard-Colin V, Aup\u00e9rin A, Pillon M et al (2020) Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children. N Engl J Med 382(23):2207\u20132219. https:\/\/doi.org\/10.1056\/NEJMoa1915315","journal-title":"N Engl J Med"},{"key":"6839_CR12","doi-asserted-by":"publisher","unstructured":"Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2004) The Biology of CD20 and Its Potential as a Target for mAb Therapy. In: Stohl W (ed) Current Directions in Autoimmunity, KARGER 8:140\u2013174. https:\/\/doi.org\/10.1159\/000082102","DOI":"10.1159\/000082102"},{"issue":"2","key":"6839_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jaci.2021.03.041","volume":"148","author":"R Labrosse","year":"2021","unstructured":"Labrosse R, Barmettler S, Derfalvi B et al (2021) Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. J Allergy Clin Immunol 148(2):523-532.e8. https:\/\/doi.org\/10.1016\/j.jaci.2021.03.041","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"6839_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","volume":"36","author":"EAA Christou","year":"2017","unstructured":"Christou EAA, Giardino G, Worth A, Ladomenou F (2017) Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab. Int Rev Immunol 36(6):352\u2013359. https:\/\/doi.org\/10.1080\/08830185.2017.1346092","journal-title":"Int Rev Immunol"},{"key":"6839_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.671503","volume":"12","author":"J Tieu","year":"2021","unstructured":"Tieu J, Smith RM, Gopaluni S et al (2021) Rituximab associated hypogammaglobulinemia in autoimmune disease. Front Immunol 12:671503. https:\/\/doi.org\/10.3389\/fimmu.2021.671503","journal-title":"Front Immunol"},{"issue":"6","key":"6839_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/acr.22993","volume":"69","author":"V Reddy","year":"2017","unstructured":"Reddy V, Martinez L, Isenberg DA, Leandro MJ, Cambridge G (2017) Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long\u2010term effects on serum immunoglobulins. Arthritis Care Res 69(6):857\u2013866. https:\/\/doi.org\/10.1002\/acr.22993","journal-title":"Arthritis Care Res"},{"issue":"10","key":"6839_CR17","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","volume":"53","author":"E Besada","year":"2014","unstructured":"Besada E, Koldingsnes W, Nossent JC (2014) Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology 53(10):1818\u20131824. https:\/\/doi.org\/10.1093\/rheumatology\/keu194","journal-title":"Rheumatology"},{"issue":"4","key":"6839_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s10157-020-01858-z","volume":"24","author":"S Fujinaga","year":"2020","unstructured":"Fujinaga S, Tomii Y (2020) Profound effect of post-rituximab mycophenolate mofetil administration for persistent hypogammaglobulinemia in young children with steroid-dependent nephrotic syndrome. Clin Exp Nephrol 24(4):386\u2013387. https:\/\/doi.org\/10.1007\/s10157-020-01858-z","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"6839_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/BOR.0000000000000272","volume":"28","author":"R Kado","year":"2016","unstructured":"Kado R, Sanders G, McCune WJ (2016) Suppression of normal immune responses after treatment with rituximab. Curr Opin Rheumatol 28(3):251\u2013258. https:\/\/doi.org\/10.1097\/BOR.0000000000000272","journal-title":"Curr Opin Rheumatol"},{"key":"6839_CR20","doi-asserted-by":"publisher","unstructured":"Venhoff N, Effelsberg NM, Salzer U, Bob\u00e9 P et al (2012) Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides. PLoS One 7(5):e37626. https:\/\/doi.org\/10.1371\/journal.pone.0037626","DOI":"10.1371\/journal.pone.0037626"},{"issue":"1","key":"6839_CR21","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1136\/annrheumdis-2020-217549","volume":"80","author":"P Guilpain","year":"2021","unstructured":"Guilpain P, Le Bihan C, Foulongne V et al (2021) Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia. Ann Rheum Dis 80(1):e10\u2013e10. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217549","journal-title":"Ann Rheum Dis"},{"key":"6839_CR22","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. Published online March 29, 2021:n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"issue":"7650","key":"6839_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"4","key":"6839_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383\u2013394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"6839_CR25","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, et al (2020) Systematic reviews of etiology and risk . Chapter 7. In: JBI manual for evidence synthesis. JBI. https:\/\/synthesismanual.jbi.global","DOI":"10.46658\/JBIRM-17-06"},{"issue":"3","key":"6839_CR26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1006\/clim.1999.4799","volume":"93","author":"ME Conley","year":"1999","unstructured":"Conley ME, Notarangelo LD, Etzioni A (1999) Diagnostic criteria for primary immunodeficiencies. Clin Immunol 93(3):190\u2013197. https:\/\/doi.org\/10.1006\/clim.1999.4799","journal-title":"Clin Immunol"},{"issue":"3","key":"6839_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1081-1206(10)60665-5","volume":"99","author":"S Agarwal","year":"2007","unstructured":"Agarwal S, Cunningham-Rundles C (2007) Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol 99(3):281\u2013283. https:\/\/doi.org\/10.1016\/S1081-1206(10)60665-5","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"6839_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/clinchem\/28.1.126","volume":"28","author":"CR Jolliff","year":"1982","unstructured":"Jolliff CR, Cost KM, Stivrins PC et al (1982) Reference intervals for serum IgG, IgA, IgM, C3, and C4 as determined by rate nephelometry. Clin Chem 28(1):126\u2013128","journal-title":"Clin Chem"},{"issue":"4","key":"6839_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088. https:\/\/doi.org\/10.2307\/2533446","journal-title":"Biometrics"},{"issue":"7109","key":"6839_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"6839_CR31","doi-asserted-by":"publisher","unstructured":"Fisher DJ, Zwahlen M, Egger M, Higgins JPT (2022) Meta\u2010Analysis in Stata. In: Egger M, Higgins JPT, Davey Smith G (eds) Systematic Reviews in Health Research, 1st ed. Wiley, pp 481\u2013509. https:\/\/doi.org\/10.1002\/9781119099369.ch25","DOI":"10.1002\/9781119099369.ch25"},{"key":"6839_CR32","unstructured":"RC TEAM. R: a language and environment for statistical computing. R Found Stat Comput. https:\/\/www.R-project.org\/. Accessed 9 Sept 2024"},{"key":"6839_CR33","doi-asserted-by":"publisher","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metafor Package. J Stat Softw 36(3). https:\/\/doi.org\/10.18637\/jss.v036.i03","DOI":"10.18637\/jss.v036.i03"},{"issue":"11","key":"6839_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112658","volume":"9","author":"EG Kamburova","year":"2014","unstructured":"Kamburova EG, Koenen HJPM, Van Den Hoogen MWF, Baas MC, Joosten I, Hilbrands LB, Borrow R (2014) Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. PLoS ONE 9(11):e112658. https:\/\/doi.org\/10.1371\/journal.pone.0112658","journal-title":"PLoS ONE"},{"issue":"1","key":"6839_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJM197507032930103","volume":"293","author":"J Giangiacomo","year":"1975","unstructured":"Giangiacomo J, Cleary TG, Cole BR, Hoffsten P, Robson AM (1975) Serum immunoglobulins in the nephrotic syndrome: a possible cause of minimal-change nephrotic syndrome. N Engl J Med 293(1):8\u201312. https:\/\/doi.org\/10.1056\/NEJM197507032930103","journal-title":"N Engl J Med"},{"issue":"6","key":"6839_CR36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(6):909\u2013920. https:\/\/doi.org\/10.1136\/ard.2010.144998","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6839_CR37","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00467-021-05304-4","volume":"37","author":"Y Inoki","year":"2022","unstructured":"Inoki Y, Kamei K, Nishi K, Sato M, Ogura M, Ishiguro A (2022) Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. Pediatr Nephrol 37(5):1057\u20131066. https:\/\/doi.org\/10.1007\/s00467-021-05304-4","journal-title":"Pediatr Nephrol"},{"key":"6839_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01653","volume":"10","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Serafinelli J et al (2019) Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome. Front Immunol 10:1653. https:\/\/doi.org\/10.3389\/fimmu.2019.01653","journal-title":"Front Immunol"},{"issue":"2","key":"6839_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"E Chan","year":"2020","unstructured":"Chan E, Webb H, Yu E et al (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97(2):393\u2013401. https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","journal-title":"Kidney Int"},{"issue":"6","key":"6839_CR40","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"E Chan","year":"2022","unstructured":"Chan E, Yu ELM, Angeletti A et al (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33(6):1193\u20131207. https:\/\/doi.org\/10.1681\/ASN.2021111472","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"6839_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4169","journal-title":"JAMA Netw Open"},{"issue":"11","key":"6839_CR42","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00467-013-2538-0","volume":"28","author":"M Mantan","year":"2013","unstructured":"Mantan M, Pandharikar N, Yadav S, Chakravarti A, Sethi GR (2013) Seroprotection for hepatitis B in children with nephrotic syndrome. Pediatr Nephrol 28(11):2125\u20132130. https:\/\/doi.org\/10.1007\/s00467-013-2538-0","journal-title":"Pediatr Nephrol"},{"issue":"33","key":"6839_CR43","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1016\/j.vaccine.2013.05.004","volume":"31","author":"N Y\u0131ld\u0131z","year":"2013","unstructured":"Y\u0131ld\u0131z N, Sever L, Kasap\u00e7opur \u00d6, \u00c7ullu F, Ar\u0131soy N, \u00c7al\u0131\u015fkan S (2013) Hepatitis B virus vaccination in children with steroid sensitive nephrotic syndrome: immunogenicity and safety? Vaccine 31(33):3309\u20133312. https:\/\/doi.org\/10.1016\/j.vaccine.2013.05.004","journal-title":"Vaccine"},{"issue":"9","key":"6839_CR44","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s00467-023-05913-1","volume":"38","author":"A Zurowska","year":"2023","unstructured":"Zurowska A, Drozynska-Duklas M, Topaloglu R et al (2023) Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey. Pediatr Nephrol 38(9):3035\u20133042. https:\/\/doi.org\/10.1007\/s00467-023-05913-1","journal-title":"Pediatr Nephrol"},{"key":"6839_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2014.11.004","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM et al (2015) Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun 57:24\u201329. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.004","journal-title":"J Autoimmun"},{"issue":"2","key":"6839_CR46","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36321","volume":"4","author":"CL McAtee","year":"2021","unstructured":"McAtee CL, Lubega J, Underbrink K et al (2021) Association of rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open 4(2):e2036321. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.36321","journal-title":"JAMA Netw Open"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-06839-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-06839-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-06839-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:53:52Z","timestamp":1776930832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-06839-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6839"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-06839-0","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}